INZY NASDAQ
Inozyme Pharma, Inc.
1W: +0.2%
1M: +0.5%
3M: +359.8%
1Y: -10.3%
3Y: -22.5%
$4.00
Last traded 2025-07-02 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+100.0% ▲
Operating Income
-$104M
-37.5% ▼
Net Income
-$102M
-43.4% ▼
EPS (Diluted)
$-1.62
-18.2% ▼
EBITDA
-$104M
-39.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $217K | $1M | $1M | $1M | $0 |
| Gross Profit | -$217K | -$1M | -$1M | -$1M | $0 |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $46M | $38M | $48M | $54M | $83M |
| SG&A Expenses | $11M | $19M | $21M | $21M | $21M |
| Operating Expenses | $57M | $57M | $69M | $76M | $104M |
| Operating Income | -$57M | -$57M | -$69M | -$76M | -$104M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $0 | $0 | $0 | $3M | -$6M |
| Income Before Tax | -$56M | -$57M | -$67M | -$71M | -$102M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$56M | -$56M | -$65M | -$71M | -$102M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-2.39 | $-2.39 | $-1.73 | $-1.37 | $-1.62 |
| EBITDA | -$57M | -$56M | -$66M | -$75M | -$104M |
| Shares Outstanding | 23M | 24M | 38M | 52M | 63M |